Literature DB >> 7829674

Which proliferation markers for routine immunohistology? A comparison of five antibodies.

D S Rose1, P H Maddox, D C Brown.   

Abstract

AIMS: To determine the best of five antibodies for immunohistochemical assessment of growth fraction in formalin fixed, paraffin wax embedded tissues.
METHODS: Sections from 100 recent, and 17 ten year old or over wax embedded blocks of normal and malignant tissues were immunostained with monoclonal Ki67, polyclonal Ki67, PC10, MIB1, and JC1. The antibodies were evaluated for specificity of nuclear versus cytoplasmic staining, cleanliness of background, and compared with the expected pattern of staining in normal tissues, defined immunohistochemically by monoclonal Ki67 antibody in frozen tissues or by tritiated thymidine uptake.
RESULTS: No marker was ideal, but best results were obtained with MIB1 and polyclonal Ki67, followed by JC1, PC10, and monoclonal Ki67.
CONCLUSIONS: For routine use, MIB1 or polyclonal Ki67 are the best proliferation markers in conventional histological preparations. The other markers tested cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829674      PMCID: PMC503063          DOI: 10.1136/jcp.47.11.1010

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  37 in total

Review 1.  Flow cytometry: methodology and applications in pathology.

Authors:  P Quirke; J E Dyson
Journal:  J Pathol       Date:  1986-06       Impact factor: 7.996

2.  Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus.

Authors:  S G Silverberg
Journal:  Hum Pathol       Date:  1976-07       Impact factor: 3.466

3.  The relationship between growth rate, labelling index and histological type of human solid tumours.

Authors:  E P Malaise; N Chavaudra; M Tubiana
Journal:  Eur J Cancer       Date:  1973-04       Impact factor: 9.162

4.  Uterine sarcomas. Classification, diagnosis, and prognosis.

Authors:  R L Kempson; W Bari
Journal:  Hum Pathol       Date:  1970-09       Impact factor: 3.466

5.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

6.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

7.  Mitosis counting--a need for reappraisal.

Authors:  P S Ellis; R Whitehead
Journal:  Hum Pathol       Date:  1981-01       Impact factor: 3.466

8.  New approach to assessing lung tumours in man.

Authors:  K C Gatter; M S Dunnill; J Gerdes; H Stein; D Y Mason
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

9.  Cell proliferation and its relationship to clinical features and relapse in breast cancers.

Authors:  C Gentili; O Sanfilippo; R Silvestrini
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

10.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

View more
  18 in total

1.  Comparison of Ki-67 equivalent antibodies.

Authors:  C F Lindboe; S H Torp
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

2.  Ki-67 expression in early prostate cancer and associated pathological lesions.

Authors:  M R Feneley; M P Young; C Chinyama; R S Kirby; M C Parkinson
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

3.  Which proliferation markers for routine immunohistology?

Authors:  J Southgate; P Harnden; J Holt
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

4.  Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases.

Authors:  M J Edel; J M Harvey; J M Papadimitriou
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Environmental enrichment rescues postnatal neurogenesis defect in the male and female Ts65Dn mouse model of Down syndrome.

Authors:  Lina Chakrabarti; Joseph Scafidi; Vittorio Gallo; Tarik F Haydar
Journal:  Dev Neurosci       Date:  2011-08-25       Impact factor: 2.984

6.  Proliferation indexes--a comparison between cutaneous basal and squamous cell carcinomas.

Authors:  M H al-Sader; E Doyle; E W Kay; M Bennett; C B Walsh; B Curran; C Milburn; M Leader
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

7.  Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype.

Authors:  Srirupa Roy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert Sclafani; Rajesh Agarwal
Journal:  Cell Cycle       Date:  2008-06-30       Impact factor: 4.534

Review 8.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

9.  Proliferative Activity in Pancreatic Endocrine Tumors: Association with Function, Metastases, and Survival.

Authors:  Martha R. Clarke; Evan E. Baker; Robert J. Weyant; Lisa Hill; Sally E. Carty
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  CD26 (Dipeptidyl Aminopeptidase IV) Expression in Normal and Diseased Human Thyroid Glands.

Authors:  Marcus A. Lima; Valeria A. Gontijo; Fernando C. L. Schmitt
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.